Publication details

CANVAS – Canagliflozin a kardiovaskulární a renální vliv u diabetes mellitus 2. Typu

Authors

VÍTOVEC Jiří ŠPINAR Jindřich ŠPINAROVÁ Lenka

Year of publication 2019
Type Article in Periodical
Magazine / Source Kardiologická revue
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.kardiologickarevue.cz/casopisy/kardiologicka-revue/2019-1-12/canvas-canagliflozin-a-kardiovaskularni-a-renalni-vliv-u-diabetes-mellitus-2-typu-109103
Keywords Canagliflozin; Cardiovascular and renal safety; Programme CANVAS; Type 2 diabetes mellitus
Description Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycaemia as well as blood pressure, body weight, and albuminuria in people with diabetes. The CANVAS Programme integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Conclusions: In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a significantly lower risk of cardiovascular events than those who received placebo. A boundary higher risk of amputation, primarily at the level of the toe or metatarsus was observed in the study. These complications, however, were not proved in subsequent observational databases. © 2019, Ambit Media a.s.. All rights reserved.

You are running an old browser version. We recommend updating your browser to its latest version.

More info